BCTX
BriaCell Therapeutics Corp.Company Information
- Company Name
- BriaCell Therapeutics Corp.
- CIK
- CIK0001610820
- Category
- <br>Emerging growth company
- Ticker: Exchange
- BCTX: Nasdaq, BCTXL: Nasdaq, BCTXZ: Nasdaq
- Fiscal Year End
- July 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BCTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-14
- Last sale
- —
- Shares purchased (TTM)
- 902,935
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 451,422
- Shares outstanding
- 7,250,487
- Ownership
- 6.23%
Earnings Market Reaction
- Filing date
- 2026-06-09
- Price on filing date
- —
- 1-month reaction
- 6.19%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 7 | 30 | 3 | 10 | 12 | 5 | 6 | 1 | 1 | 6 | 14 | 21 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | 5 | 5 | 5 | 6 | ||||||
| Short Term Investments | 16 | - | 7 | 7 | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 25 | 32 | 11 | 20 | 15 | 7 | 8 | 4 | 6 | 12 | 18 | 27 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Equity Securities F V N I Noncurrent | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | ||||||
| Intangible Assets Net Including Goodwill | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Prepaid Expense Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | ||||||
| Assets Noncurrent | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | ||||||
| Assets | 27 | 34 | 13 | 22 | 17 | 9 | 10 | 6 | 6 | 12 | 19 | 27 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | 2 | 2 | 2 | 3 | 3 | 5 | 4 | 7 | 6 | 4 | 0 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Liabilities Current | 4 | 3 | 3 | 4 | 4 | 5 | 5 | 7 | 7 | 4 | 1 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 6 | - | - | 29 | ||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 6 | 17 | 15 | 29 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 117 | 117 | 102 | 102 | 94 | 85 | 82 | 72 | 70 | 70 | 70 | 70 | ||||||
| Additional Paid In Capital | - | - | - | - | - | - | - | - | - | - | 8 | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Minority Interest | -1 | -1 | -1 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | ||||||
| Retained Earnings Accumulated Deficit | -134 | -127 | -120 | -112 | -104 | -98 | -91 | -85 | -84 | -86 | -75 | -81 | ||||||
| Stockholders Equity | 23 | 30 | 9 | 17 | 12 | 3 | 4 | -3 | -6 | -8 | 3 | -4 | ||||||
| Liabilities And Stockholders Equity | 27 | 34 | 13 | 22 | 17 | 9 | 10 | 6 | 6 | 12 | 19 | 27 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0.00 | - | 0.00 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Common Stock Shares Issued | 7 | 7 | - | 2 | 7 | - | 36 | 0 | 16 | 16 | 16 | 16 | ||||||
| Shares Outstanding | 7 | 7 | - | 2 | 7 | 0 | 36 | 0 | 16 | 16 | 16 | 16 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBriaCell Therapeutics Corp. (BCTX) — SEC Financial Statements & Analysis
BriaCell Therapeutics Corp. (BCTX) is a pharmaceutical preparations company, incorporated in A1. BriaCell Therapeutics Corp. trades on Nasdaq as: BCTX, BCTXL, BCTXZ. BriaCell Therapeutics Corp. (BCTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-04-30, filed with the SEC on 2026-06-09. Based on that filing, BriaCell Therapeutics Corp. carries a market cap of $30.31M, a P/E ratio of -0.98x, a P/B ratio of 1.29x, an enterprise value of $23.43M, and an EV/EBITDA multiple of -0.73x. On profitability, it posts a Return on Equity (ROE) of -175.81%, a Return on Assets (ROA) of -141.02%, and a Return on Invested Capital (ROIC) of -400.12%. Per share, it reports EPS of $-4.29, diluted EPS of $-4.29, free cash flow per share of $-6.43, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 59.90% year-over-year and EPS growth of -91.77% year-over-year. On the balance sheet, it maintains a current ratio of 7.07x, a quick ratio of 7.07x, working capital of $21.80M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, free cash flow of $-46.62M (TTM), and net debt of $-6.88M. Figures sourced from SEC EDGAR.
- Market Cap
- $30.31M
- P/E TTM
- -0.98x
- EPS TTM
- $-4.29
- P/B TTM
- 1.29x
- ROE TTM
- -175.81%
- ROA TTM
- -141.02%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-46.62M
Data as of 2026-04-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BriaCell Therapeutics Corp. in?
BriaCell Therapeutics Corp. (BCTX) operates in the Pharmaceutical Preparations industry.
What exchange does BCTX trade on?
BriaCell Therapeutics Corp. (BCTX) trades on the Nasdaq.
Where is BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. is incorporated in British Columbia, Canada.
When was BriaCell Therapeutics Corp. (BCTX)'s most recent SEC filing?
BriaCell Therapeutics Corp. (BCTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-04-30, filed with the SEC on 2026-06-09.
What is BCTX's market cap?
BriaCell Therapeutics Corp. (BCTX) has a market capitalization of $30.31M as of 2026-04-30.
What is BCTX's EPS (earnings per share)?
BriaCell Therapeutics Corp. (BCTX)'s trailing twelve month EPS is $-4.29 as of 2026-04-30.
What is BCTX's ROE (return on equity)?
BriaCell Therapeutics Corp. (BCTX)'s trailing twelve month Return on Equity (ROE) is -175.81% as of 2026-04-30.
What is BCTX's ROA (return on assets)?
BriaCell Therapeutics Corp. (BCTX)'s trailing twelve month Return on Assets (ROA) is -141.02% as of 2026-04-30.
What is BCTX's ROIC (return on invested capital)?
BriaCell Therapeutics Corp. (BCTX)'s trailing twelve month Return on Invested Capital (ROIC) is -400.12% as of 2026-04-30.
What is BCTX's EV/EBITDA?
BriaCell Therapeutics Corp. (BCTX)'s trailing twelve month EV/EBITDA is -0.73x as of 2026-04-30.